Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23:e333–e465.

Article  PubMed  Google Scholar 

Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991;9:1215–23.

Article  PubMed  CAS  Google Scholar 

Ishida S, Doki N, Shingai N, Yoshioka K, Kakihana K, Sakamaki H, et al. The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ann Hematol. 2016;95:1145–50.

Article  PubMed  CAS  Google Scholar 

Marumo A, Omori I, Tara S, Otsuka Y, Konuma R, Adachi H, et al. Cyclophosphamide-induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120 mg/kg or less. Asia Pac J Clin Oncol. 2022;18:e507–e14.

Article  PubMed  Google Scholar 

Rotz S, Hamilton BK. Post-transplantation cyclophosphamide: an old nemesis to a new transplant paradigm?. JACC CardioOncol. 2021;3:260–2.

Article  PubMed  PubMed Central  Google Scholar 

Dulery R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol. 2021;3:250–9.

Article  PubMed  PubMed Central  Google Scholar 

Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, et al. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv. 2021;5:5599–607.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Perez-Valencia AI, Cascos E, Carbonell-Ordeig S, Charry P, Gomez-Hernando M, Rodriguez-Lobato LG, et al. Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant. Blood Adv. 2023;7:2018–31.

Article  PubMed  CAS  Google Scholar 

Lin CJ, Vader JM, Slade M, DiPersio JF, Westervelt P, Romee R. Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation. Cancer. 2017;123:1800–9.

Article  PubMed  CAS  Google Scholar 

Snowden JA, Sanchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 2022;57:1217–39.

Article  Google Scholar 

Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for transplantation and cellular therapy. Biol Blood Marrow Transpl. 2020;26:1247–56.

Article  CAS  Google Scholar 

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 2018;53:1401–15.

Article  Google Scholar 

Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transpl. 2016;22:4–10.

Article  Google Scholar 

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21:389–401.e1.

Article  Google Scholar 

Sureda A, Carpenter PA, Bacigalupo A, Bhatt VR, de la Fuente J, Ho A, et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transpl. 59:832–837.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.

Article  CAS  Google Scholar 

Tichelli A, Bhatia S, Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol. 2008;142:11–26.

Article  PubMed  Google Scholar 

Tichelli A, Passweg J, Wojcik D, Rovo A, Harousseau JL, Masszi T, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:1203–10.

Article  PubMed  Google Scholar 

Iqubal A, Iqubal MK, Sharma S, Ansari MA, Najmi AK, Ali SM, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sci. 2019;218:112–31.

Article  PubMed  CAS  Google Scholar 

Nishikawa T, Miyahara E, Kurauchi K, Watanabe E, Ikawa K, Asaba K, et al. Mechanisms of fatal cardiotoxicity following high-dose cyclophosphamide therapy and a method for its prevention. PLoS One. 2015;10:e0131394.

Article  PubMed  PubMed Central  Google Scholar 

Tolosa-Ridao C, Cascos E, Rodriguez-Lobato LG, Pedraza A, Suarez-Lledo M, Charry P, et al. EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2024.59:974–982

Martinez-Sanchez J, Pascual-Diaz R, Palomo M, Moreno-Castano AB, Ventosa H, Salas MQ, et al. Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro. Bone Marrow Transpl. 2023;58:407–13.

Article  CAS  Google Scholar 

Moreno-Castano AB, Salas MQ, Palomo M, Martinez-Sanchez J, Rovira M, Fernandez-Aviles F, et al. Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development. Front Immunol. 2022;13:1050994.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dulery R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R, et al. Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transpl. 2023;58:1215–22.

Article  CAS  Google Scholar 

Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, et al. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial. Br J Haematol. 2023;200:210–21.

Article  PubMed  CAS  Google Scholar 

Zu Y, Li Z, Gui R, Liu Y, Zhang Y, Yu F, et al. Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial. Bone Marrow Transpl. 2022;57:1573–80.

Article  CAS  Google Scholar 

Garcia-Cadenas I, Redondo S, Esquirol A, Portos JM, Novelli S, Saavedra S, et al. Successful outcome in patients with myelofibrosis undergoing allogeneic donor hematopoietic cell transplantation using reduced doses of post-transplantation cyclophosphamide: challenges and review of the literature. Transpl Cell Ther. 2023;29:473.e1–e6.

Article  CAS  Google Scholar 

Yanagisawa R, Tamaki M, Tanoshima R, Misaki Y, Uchida N, Koi S, et al. Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group. Hematol Oncol. 2023;41:535–45.

Article  PubMed  Google Scholar 

Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013;49:2900–9.

Article  PubMed  CAS  Google Scholar 

Li X, Li Y, Zhang T, Xiong X, Liu N, Pang B, et al. Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials. Pharm Res. 2020;151:104577.

Article  CAS  Google Scholar 

Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120:4285–91.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378–85.

Article  PubMed  PubMed Central  CAS  Go